The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum.
Spiperone 0.1-10 mg/kg i.p. increased the accumulation of Dopa in the rat striatum after Dopa decarboxylase inhibition. Approximately 50% of the rats treated with doses 1 mg/kg or higher showed cataleptic symptoms. Binding studies performed on the striatal tissues from these rats showed a dose-dependent lowering of the maximal binding of spiperone. The decrease in B max was significant at doses of spiperone 1 mg/kg or higher. Thus at 1 and 10 mg/kg, significant effects on binding, Dopa accumulation, and behaviour were found to coexist.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001665:Binding Sites; D002375:Catalepsy / Q000139:chemically induced; D003342:Corpus Striatum / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000378:metabolism*; D006220:Haloperidol / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D006900:Hydroxylation; D008238:Lysergic Acid Diethylamide / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013134:Spiperone / Q000378:metabolism / Q000494:pharmacology; D014443:Tyrosine / Q000378:metabolism*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D014443:Tyrosine; D013134:Spiperone; D004295:Dihydroxyphenylalanine; D008238:Lysergic Acid Diethylamide; D006220:Haloperidol